Gregory Brandt, MD

Gregory Brandt, MD

Professor of Clinical Pediatrics - Pediatric Hematology-Oncology, Pediatric Hematology/Oncology
Pediatrics

    About me

    Gregory Brandt, MD, is a professor of clinical pediatrics at SIU School of Medicine, specializing in pediatric hematology/oncology. He completed a fellowship in Pediatric Hematology/Oncology/Bone Marrow Transplant at Children’s Hospital Medical Center in Cincinnati, Ohio, and a pediatric residency at St. Louis University/Cardinal Glennon Children’s Hospital in St. Louis, Missouri. Board certified in pediatric hematology/oncology, Brandt is a member of the Children’s Oncology Group and serves as SIU’s principle investigator for research studies.

    Gender

    Male

    Education & training

    Positions
    Pediatric Hematology Oncologist
    Board Certifications
    Pediatric Hematology Oncology
    Medical School
    St. Louis University, School of Medicine, St. Louis, MO
    Residency
    St. Louis University School of Medicine, St. Louis, MO - Pediatrics
    Fellowship
    Children's Hospital Medical Center, Cincinnati, OH - Hematology, Oncology, and Bone Marrow Transplant

    Featured Publications

    [1] Singh N.  Brandt G.  Torky A.  Ganta A.  Rebound Hypercalcemia in a 14-Year-Old After Denosumab Therapy for Giant Cell Granuloma of the Mandible.  2025 ;12(4):300-303. 
    PMID: 41467132

    [2] Bielack SS.  Smeland S.  Whelan JS.  Marina N.  Jovic G.  Hook JM.  Krailo MD.  Gebhardt M.  Pápai Z.  Meyer J.  Nadel H.  Randall RL.  Deffenbaugh C.  Nagarajan R.  Brennan B.  Letson GD.  Teot LA.  Goorin A.  Baumhoer D.  Kager L.  Werner M.  Lau CC.  Sundby Hall K.  Gelderblom H.  Meyers P.  Gorlick R.  Windhager R.  Helmke K.  Eriksson M.  Hoogerbrugge PM.  Schomberg P.  Tunn PU.  Kühne T.  Jürgens H.  van den Berg H.  Böhling T.  Picton S.  Renard M.  Reichardt P.  Gerss J.  Butterfass-Bahloul T.  Morris C.  Hogendoorn PC.  Seddon B.  Calaminus G.  Michelagnoli M.  Dhooge C.  Sydes MR.  Bernstein M.  .  Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.  2015 Jul;33(20):2279-87. 
    PMID: 26033801

    Grants

    •Grant: Principal Investigator, Children’s Oncology Group, Ongoing.

    Related articles

    Cal & siblings

    A year after leukemia diagnosis, clinical trial brings hope

    When their 4-year-old son was stricken with leukemia, Chad and Regan Hoesman turned to the children's cancer specialists at SIU Medicine and hoped for the best. A year into his treatment, their little boy received a big gift.